Cargando…
Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial
BACKGROUND: We assessed immunogenicity of three-dose and two-dose immunization schedules with a Sabin-strain inactivated poliovirus vaccine (sIPV) produced by one Chinese vaccine manufacturer. METHODS: This was an open label, randomized, controlled trial conducted in 16 vaccination clinics in Shando...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315596/ https://www.ncbi.nlm.nih.gov/pubmed/34327346 http://dx.doi.org/10.1016/j.lanwpc.2021.100133 |
_version_ | 1783729749036630016 |
---|---|
author | Wang, Yamin Xu, Qing Jeyaseelan, Vishali Ying, Zhifang Mach, Ondrej Sutter, Roland Wen, Ning Rodewald, Lance Li, Changgui Wang, Jie Yuan, Hui Yin, Zundong Feng, Zijian Xu, Aiqiang An, Zhijie |
author_facet | Wang, Yamin Xu, Qing Jeyaseelan, Vishali Ying, Zhifang Mach, Ondrej Sutter, Roland Wen, Ning Rodewald, Lance Li, Changgui Wang, Jie Yuan, Hui Yin, Zundong Feng, Zijian Xu, Aiqiang An, Zhijie |
author_sort | Wang, Yamin |
collection | PubMed |
description | BACKGROUND: We assessed immunogenicity of three-dose and two-dose immunization schedules with a Sabin-strain inactivated poliovirus vaccine (sIPV) produced by one Chinese vaccine manufacturer. METHODS: This was an open label, randomized, controlled trial conducted in 16 vaccination clinics in Shandong province. Infants were allocated randomly to either a 3-dose study arm (sIPV administered at 2, 3, and 4 months of age) or a 2-dose arm (sIPV administered at 4 and 8–11 months of age). Poliovirus neutralizing antibodies were measured in sera collected prior to the first sIPV dose and one month after the last dose. FINDINGS: We enrolled 560 infants; 536 (95.7%) completed the study. Final seropositivity rates were >98% for all three serotypes in both study arms. There were no statistically significant differences in seropositivity between the 2-dose and the 3-dose schedule. Final median reciprocal titres of polio antibodies were high overall (>1:768 for all serotypes) and statistically significantly higher in 2-dose recipients compared with 3-dose recipients (p < 0.001). INTERPRETATION: This study offers evidence that two doses of sIPV administered at 4 and 8–11 months of age and three doses of sIPV administered at 2, 3, and 4 months of age both provide serological protection against poliomyelitis. Median reciprocal titres of polio antibodies were high overall, and were more related to the interval between doses than the number of doses, with the longer interval of the 2-dose schedule producing higher reciprocal titres than the shorter-interval 3-dose schedule. The protection provided by the 3-dose schedule is achieved earlier in life than the protection with the 2-dose schedule. Countries planning to use an IPV-only schedule in the post-eradication era can consider this 2-dose sIPV option as an immunogenic and dose-sparing strategy. FUNDING: World Health Organization (from a grant from International PolioPlus Committee, Rotary International, Evanston, IL, USA). |
format | Online Article Text |
id | pubmed-8315596 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-83155962021-07-28 Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial Wang, Yamin Xu, Qing Jeyaseelan, Vishali Ying, Zhifang Mach, Ondrej Sutter, Roland Wen, Ning Rodewald, Lance Li, Changgui Wang, Jie Yuan, Hui Yin, Zundong Feng, Zijian Xu, Aiqiang An, Zhijie Lancet Reg Health West Pac Research Paper BACKGROUND: We assessed immunogenicity of three-dose and two-dose immunization schedules with a Sabin-strain inactivated poliovirus vaccine (sIPV) produced by one Chinese vaccine manufacturer. METHODS: This was an open label, randomized, controlled trial conducted in 16 vaccination clinics in Shandong province. Infants were allocated randomly to either a 3-dose study arm (sIPV administered at 2, 3, and 4 months of age) or a 2-dose arm (sIPV administered at 4 and 8–11 months of age). Poliovirus neutralizing antibodies were measured in sera collected prior to the first sIPV dose and one month after the last dose. FINDINGS: We enrolled 560 infants; 536 (95.7%) completed the study. Final seropositivity rates were >98% for all three serotypes in both study arms. There were no statistically significant differences in seropositivity between the 2-dose and the 3-dose schedule. Final median reciprocal titres of polio antibodies were high overall (>1:768 for all serotypes) and statistically significantly higher in 2-dose recipients compared with 3-dose recipients (p < 0.001). INTERPRETATION: This study offers evidence that two doses of sIPV administered at 4 and 8–11 months of age and three doses of sIPV administered at 2, 3, and 4 months of age both provide serological protection against poliomyelitis. Median reciprocal titres of polio antibodies were high overall, and were more related to the interval between doses than the number of doses, with the longer interval of the 2-dose schedule producing higher reciprocal titres than the shorter-interval 3-dose schedule. The protection provided by the 3-dose schedule is achieved earlier in life than the protection with the 2-dose schedule. Countries planning to use an IPV-only schedule in the post-eradication era can consider this 2-dose sIPV option as an immunogenic and dose-sparing strategy. FUNDING: World Health Organization (from a grant from International PolioPlus Committee, Rotary International, Evanston, IL, USA). Elsevier 2021-04-16 /pmc/articles/PMC8315596/ /pubmed/34327346 http://dx.doi.org/10.1016/j.lanwpc.2021.100133 Text en © 2021 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/3.0/igo/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/igo/). |
spellingShingle | Research Paper Wang, Yamin Xu, Qing Jeyaseelan, Vishali Ying, Zhifang Mach, Ondrej Sutter, Roland Wen, Ning Rodewald, Lance Li, Changgui Wang, Jie Yuan, Hui Yin, Zundong Feng, Zijian Xu, Aiqiang An, Zhijie Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial |
title | Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial |
title_full | Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial |
title_fullStr | Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial |
title_full_unstemmed | Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial |
title_short | Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial |
title_sort | immunogenicity of two-dose and three-dose vaccination schedules with sabin inactivated poliovirus vaccine in china: an open-label, randomized, controlled trial |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315596/ https://www.ncbi.nlm.nih.gov/pubmed/34327346 http://dx.doi.org/10.1016/j.lanwpc.2021.100133 |
work_keys_str_mv | AT wangyamin immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial AT xuqing immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial AT jeyaseelanvishali immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial AT yingzhifang immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial AT machondrej immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial AT sutterroland immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial AT wenning immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial AT rodewaldlance immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial AT lichanggui immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial AT wangjie immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial AT yuanhui immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial AT yinzundong immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial AT fengzijian immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial AT xuaiqiang immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial AT anzhijie immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial |